|
49 Companies |
|
54 Products |
|
54 Products |
|
60 Mechanisms of Action |
|
1 Trial |
|
194 News |
|
| «1234» |
- | oxaliplatin / Generic mfg.
Trial completion: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (clinicaltrials.gov) - Feb 22, 2014
P2, N=180, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=637, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | ABT-751 / AbbVie, Eisai
Trial completion: ABT-751 in Treating Young Patients With Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=90, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, patupilone (EPO 906) / Novartis
Trial completion: Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
No longer recruiting --> Completed Recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion, Metastases: Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller, Metastases: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=75, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: COG-AEWS0031: Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor (clinicaltrials.gov) - Feb 19, 2014
P3, N=587, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | temozolomide / Generic mfg.
Trial completion: Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=30, Completed, Sponsor: Duke University
No longer recruiting --> Completed Recruiting --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion, Metastases: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Not yet recruiting --> Completed
- | irinotecan / Generic mfg.
Trial completion: Irinotecan in Treating Children With Refractory Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=181, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Not yet recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Surgery: Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=16, Completed, Sponsor: Fred Hutchinson Cancer Research Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Suspended --> Completed
- | Trial completion: Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Suspended --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas (clinicaltrials.gov) - Feb 19, 2014
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | plerixafor / Generic mfg.
Trial initiation date: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
No longer recruiting --> Completed Initiation date: Feb 2011 --> Feb 2014
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
Initiation date: Feb 2011 --> Feb 2014 N=67 --> 46
- | plerixafor / Generic mfg.
Enrollment open: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
N=67 --> 46 Active, not recruiting --> Recruiting
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) (clinicaltrials.gov) - Feb 16, 2014
P2, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting N=24 --> 15
- Trial termination: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
N=24 --> 15 Active, not recruiting --> Terminated; The study was terminated due to slow accrual.
- Enrollment change: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Terminated; The study was terminated due to slow accrual. N=178 --> 22
- Enrollment closed, Surgery, MRI: 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: Mayo Clinic
N=178 --> 22 Recruiting --> Active, not recruiting
- | Enrollment closed, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jan 9, 2014
P2, N=20, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jan 5, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- Rytelo (imetelstat) / Geron
New P2 trial: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 11, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Surgery: Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 25, 2013
P3, N=400, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- melphalan / Generic mfg., busulfan / Generic mfg.
New P1 trial: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Oct 23, 2013
P1, N=10, Recruiting, Sponsor: University of Louisville
- melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Oct 23, 2013
P1, N=10, Recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=20, Completed, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Not yet recruiting --> Recruiting Recruiting --> Completed
- | robatumumab (SCH 717454) / Merck (MSD)
Trial termination: A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) (clinicaltrials.gov) - Sep 12, 2013
P2, N=219, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern.
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Trial initiation date: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=15, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern. Initiation date: Mar 2013 --> Jul 2013
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=15, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- Enrollment change: Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=180 --> 0
- cyclophosphamide / Generic mfg.
Enrollment closed: Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma (clinicaltrials.gov) - Jul 8, 2013
P1/2, N=44, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=180 --> 0 Suspended --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) - Jun 30, 2013
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- cytarabine / Generic mfg.
Enrollment change: Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma (clinicaltrials.gov) - Jun 27, 2013
P2, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=20 --> 10
- Enrollment change, Metastases: Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=20 --> 10 N=528 --> 0
- Trial withdrawal: Markers of Anthracycline-Related Cardiac Muscle Injury (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: St. Jude Children's Research Hospital
N=528 --> 0 Recruiting --> Withdrawn
- Enrollment change: Markers of Anthracycline-Related Cardiac Muscle Injury (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Withdrawn N=36 --> 0
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Jun 12, 2013
P2, N=38, Completed, Sponsor: Amgen
N=36 --> 0 Active, not recruiting --> Completed
- Trial withdrawal: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Withdrawn Active, not recruiting --> Terminated; Replaced by another study
- Enrollment change: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Active, not recruiting --> Terminated; Replaced by another study N=35 --> 0
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=35 --> 0 N=45 --> 23